108 related articles for article (PubMed ID: 34838338)
1. High-grade trichoblastic carcinoma with sarcomatoid differentiation harboring TP53 and PIK3CA mutations.
Mouchard A; Monegier-Dusorbier C; Berthon P; Cribier B; Basset Seguin N; Jouenne F; Mourah S; Samimi M; Kervarrec T
Ann Dermatol Venereol; 2022 Mar; 149(1):74-77. PubMed ID: 34838338
[No Abstract] [Full Text] [Related]
2. High-grade trichoblastic carcinoma arising through malignant transformation of trichoblastoma: Immunohistochemical analysis and the expression of p53 and phosphorylated AKT.
Fusumae T; Tanese K; Takeuchi A; Takasugi A; Kawakita R; Shiraishi J; Yoshida T
J Dermatol; 2019 Jan; 46(1):57-60. PubMed ID: 30379345
[TBL] [Abstract][Full Text] [Related]
3. The molecular pathogenesis of Trichilemmal carcinoma.
Ha JH; Lee C; Lee KS; Pak CS; Sun CH; Koh Y; Chang H
BMC Cancer; 2020 Jun; 20(1):516. PubMed ID: 32493317
[TBL] [Abstract][Full Text] [Related]
4.
Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
[TBL] [Abstract][Full Text] [Related]
5. Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.
Chen X; Guo Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
J Cancer Res Clin Oncol; 2019 May; 145(5):1235-1242. PubMed ID: 30806788
[TBL] [Abstract][Full Text] [Related]
6. High-grade trichoblastic carcinoma arising in trichoblastoma: a rare adnexal neoplasm often showing metastatic spread.
Schulz T; Proske S; Hartschuh W; Kurzen H; Paul E; Wünsch PH
Am J Dermatopathol; 2005 Feb; 27(1):9-16. PubMed ID: 15677970
[TBL] [Abstract][Full Text] [Related]
7. High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.
Bataillon G; Fuhrmann L; Girard E; Menet E; Laé M; Capovilla M; Treilleux I; Arnould L; Penault-Llorca F; Rouzier R; Marchiò C; Bieche I; Vincent-Salomon A
Histopathology; 2018 Aug; 73(2):273-283. PubMed ID: 29537649
[TBL] [Abstract][Full Text] [Related]
8. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
9. Eosinophil-rich trichoblastic carcinoma with aggressive clinical course in a young man.
Toberer F; Rütten A; Requena L; Kazakov DV; Enk A; Hartschuh W; Haenssle HA
J Cutan Pathol; 2017 Nov; 44(11):986-990. PubMed ID: 28869314
[TBL] [Abstract][Full Text] [Related]
10. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes.
Kotoula V; Karavasilis V; Zagouri F; Kouvatseas G; Giannoulatou E; Gogas H; Lakis S; Pentheroudakis G; Bobos M; Papadopoulou K; Tsolaki E; Pectasides D; Lazaridis G; Koutras A; Aravantinos G; Christodoulou C; Papakostas P; Markopoulos C; Zografos G; Papandreou C; Fountzilas G
Breast Cancer Res Treat; 2016 Jul; 158(2):307-21. PubMed ID: 27369359
[TBL] [Abstract][Full Text] [Related]
11. Trichoblastic carcinoma: a comprehensive review of the literature.
Boettler MA; Shahwan KT; Abidi NY; Carr DR
Arch Dermatol Res; 2022 Jul; 314(5):399-403. PubMed ID: 33993349
[TBL] [Abstract][Full Text] [Related]
12. TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.
Fountzilas G; Giannoulatou E; Alexopoulou Z; Zagouri F; Timotheadou E; Papadopoulou K; Lakis S; Bobos M; Poulios C; Sotiropoulou M; Lyberopoulou A; Gogas H; Pentheroudakis G; Pectasides D; Koutras A; Christodoulou C; Papandreou C; Samantas E; Papakostas P; Kosmidis P; Bafaloukos D; Karanikiotis C; Dimopoulos MA; Kotoula V
Oncotarget; 2016 May; 7(22):32731-53. PubMed ID: 27129168
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of TP53/PIK3CA mutations using texture and morphology analysis on breast MRI.
Moon WK; Chen HH; Shin SU; Han W; Chang RF
Magn Reson Imaging; 2019 Nov; 63():60-69. PubMed ID: 31425802
[TBL] [Abstract][Full Text] [Related]
14. Trichoblastic carcinosarcoma in a 34-year-old woman with histopathologic and molecular analysis, including re-demonstration of a CDKN2A p.(R58*) mutation.
Kim C; Brown A; Osipov V
J Cutan Pathol; 2021 Feb; 48(2):334-339. PubMed ID: 33089535
[TBL] [Abstract][Full Text] [Related]
15. Trichoblastic carcinoma arising from colostomy.
Hashimoto D; Kuroki H; Motomura Y; Ishikawa S; Inayoshi A; Udaka N; Tanoue T; Arita T; Hirota M; Yagi Y; Baba H
Am J Surg; 2011 Oct; 202(4):e35-7. PubMed ID: 21839978
[TBL] [Abstract][Full Text] [Related]
16. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
17. Multifocal metastatic pulmonary sclerosing pneumocytoma mimicking adenocarcinoma and harboring TP53 and PIK3CA mutation: A rare case report.
Li XH; Liu HA; Zhang YT; Chen XY
Asian J Surg; 2023 Oct; 46(10):4681-4682. PubMed ID: 37268465
[No Abstract] [Full Text] [Related]
18. Comparison of mutational profiles between triple-negative and hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancers in T2N0-1M0 stage: Implications of TP53 and PIK3CA mutations in Korean early-stage breast cancers.
Lee S; Kim HY; Jung YJ; Jung CS; Im D; Kim JY; Lee SM; Oh SH
Curr Probl Cancer; 2022 Apr; 46(2):100843. PubMed ID: 35180531
[TBL] [Abstract][Full Text] [Related]
19. Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan PA; Rangachari D; Mockus SM; Spotlow V; Reddi HV; Malcolm J; Huberman MS; Joseph LJ; Kobayashi SS; Costa DB
Lung Cancer; 2017 Apr; 106():17-21. PubMed ID: 28285689
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
